AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00115765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Based Chemotherapy
Description: Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
Study NCT00115765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Based Chemotherapy
Description: Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
Study NCT00115765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
Study NCT00115765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
Study NCT04075773 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Expressive Writing
Description: The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
Study NCT04075773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
Study NCT00800865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biomarker sample collection before and after dosing with cytotoxic agent(s)
Description: Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
Study NCT00800865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biomarker sample collection before and after dosing with cytotoxic agent(s)
Description: A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
Study NCT01739920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine
Description: Povidone iodine 5% drop will be instilled into conjunctival sac.
Study NCT01739920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: 1 drop of saline solution 0.9% will be instilled into conjunctival sac.
Study NCT01785810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
Study NCT03522493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yaalom Katom
Description: Full face Gas mask
Study NCT03522493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yaalom Katom
Description: Full face Gas mask
Study NCT01310816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI-926
Description: Oral
Study NCT01310816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: oral placebo
Study NCT00955292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quarfloxin
Description: Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
Study NCT03902782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline
Study NCT03902782 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intercostal block
Description: Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline
Study NCT03902782 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ESP block
Description: As described earlier
Study NCT03902782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Intercostal block
Description: As described earlier
Study NCT03528785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid
Description: * Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle
Study NCT05542979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-003 injection
Description: HH-003 injection is administrated via I.V. infusion
Study NCT03902782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: As described earlier
Study NCT03902782 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine-epinephrine
Description: As described earlier
Study NCT03902782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: As described earlier
Study NCT05542979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administrated via I.V. infusion
Study NCT02596386 — intervention group
Intervention type: PROCEDURE
Intervention: sialometry
Description: potassium evaluation
Study NCT02596386 — intervention group
Intervention type: PROCEDURE
Intervention: blood test
Description: potassium evaluation
Study NCT01348984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal fentanyl patch
Description: TFP = transdermal fentanyl patch (50 microgram/hour)
Study NCT01348984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: group 2 = placebo patch
Study NCT03189732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin local in AT
Study NCT03189732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT03189732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00692224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc gluconate
Description: zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
Study NCT03013452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oPEP
Description: Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
Study NCT03902782 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone injection
Description: As described earlier
Study NCT03013452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic drainage
Description: Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
Study NCT03902782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: As described earlier
Study NCT03902782 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: As described earlier
Study NCT04253834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometer
Description: The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.
Study NCT04253834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GO2 Mouthpiece
Description: The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
Study NCT01897532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tablets
Study NCT02502344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle
Description: food control and intensive exercise to lose weight
Study NCT02502344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: use metformin to reduce insulin resistance
Study NCT03238313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plan A
Study NCT03238313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Toxic Life Cycle of a Cigarette
Description: Video
Study NCT02095171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX002
Study NCT02095171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00692224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
Study NCT00832221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEROQUEL XR (quetiapine)
Description: repeated dose of oral tablets, 8 times per subject
Study NCT00832221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEROQUEL IR (quetiapine)
Description: repeated dose of oral tablets, 4 times per subject
Study NCT00832221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: radioligand [11C]raclopride
Description: single dose of iv admin, 5 times per subject
Study NCT02615171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity
Description: The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
Study NCT02615171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity
Description: Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
Study NCT01713426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza
Description: Cutaneous patch
Study NCT01713426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Oral capsule
Study NCT01824134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Klean & Klear The Dandy Day Corp
Study NCT01824134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Skin Gel Herbal Answers, Inc
Study NCT02834806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNIR Ridaforolimus Eluting Coronary Stent System
Description: BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
Study NCT03525418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells
Description: Allogeneic bone marrow-derived mesenchymal stem cell
Study NCT02139124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT02139124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active
Study NCT02139124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active
Study NCT02139124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active
Study NCT02139124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 100 mg
Description: Oral 100 mg capsule - active
Study NCT03022474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Intervention
Description: The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
Study NCT01940497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
Study NCT01940497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
Study NCT01940497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
Study NCT01940497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
Study NCT03092739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PD-L1 Immunocytochemistry (ICC)
Description: PD-L1 expression in the cytological specimens will be assessed using different antibodies.
Study NCT01897532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study NCT04082130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (XCM)+(CAF)
Description: The description of this intervention has been already given before.
Study NCT03092739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PD-L1 Immunohistochemistry (IHC)
Description: PD-L1 expression in the histological specimens will be assessed using different antibodies.
Study NCT04277871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscles training (PFMT) combined with yoga
Description: All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
Study NCT04277871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscles training (PFMT) combined with yoga
Description: All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
Study NCT03162588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
Study NCT01372592 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
Study NCT03593603 — intervention group
Intervention type: DEVICE
Intervention: Nellcor™ Bedside Respiratory Monitoring System
Description: Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
Study NCT04082130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (SCTG)+(CAF)
Description: The description of this intervention has been already given before.
Study NCT03261921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
Study NCT04279457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DyeVert Plus System
Description: The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure. At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved
Study NCT04279457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized hydration protocol
Description: hydration protocol based up on the Poseidon protocol
Study NCT04084431 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
Study NCT04084431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSC
Description: optimal supportive Care (OSC) alone
Study NCT01943916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio OA/US (US and OA/US)
Description: opto-acoustic plus gray scale ultrasound
Study NCT02500160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific instrumentation (MRI)
Study NCT02500160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient specific instrumentation (CT)
Study NCT03456960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438ASA
Description: TAK-438ASA tablet.
Study NCT01943916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio gray scale ultrasound
Description: gray scale ultrasound alone
Study NCT03663036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the shoulder
Description: Clinical and radiological assessments of the shoulders and the donor sites
Study NCT01634516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary support
Description: Face to face intervention plus subsequent telephone support
Study NCT01634516 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No dietary support
Description: No face to face intervention or subsequent telephone support
Study NCT04487431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Oral single dose
Study NCT04487431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BAY1817080
Description: Oral single dose
Study NCT02972944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Study NCT02972944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment
Study NCT02902471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forced oscillations measure
Study NCT03456960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablet.
Study NCT03456960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin enteric-coated tablet.
Study NCT04130828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate
Description: Ferrous fumarate 200 mg PO PC
Study NCT04130828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Fumarate
Description: Ferrous fumarate 200 mg PO PC